Is TEVA or TLSA more undervalued in 2026?

CirclFi compares Teva Pharmaceutical Industries (TEVA) and Tiziana Life Sciences Ltd (TLSA) using 13 institutional-grade valuation models. TEVA has a Quality of Company score of 6.7/10 while TLSA scores 1.7/10.

Which is a better buy — TEVA or TLSA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do TEVA and TLSA valuations compare?

TEVA at $35.32 and TLSA at $1.41 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

TEVA vs TLSA Valuation Comparison 2026 — Intrinsic Value Analysis

TEVA

Pharmaceutical Preparations

Teva Pharmaceutical Industries

Quality

6.7

out of 10

Value Trap

SAFE

Price

$35.32

Last close

Models

12/13

Active

TLSA

Pharmaceutical Preparations

Tiziana Life Sciences Ltd

Quality

1.7

out of 10

Value Trap

—

Price

$1.41

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	TEVA Fair Value	TEVA Upside	TLSA Fair Value	TLSA Upside
Bayesian DCF	Intrinsic	$8.96	-74.6%	$0.43	-69.8%
Earnings Power Value	Intrinsic	$26.28	-25.6%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$45.25	+28.1%	$1.41	+0.3%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for TEVA vs TLSA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

TEVA vs TLSA — Which Stock Is More Undervalued?

TEVA scores higher with a 6.7/10 quality rating vs TLSA's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Teva Pharmaceutical Industries (TEVA) and Tiziana Life Sciences Ltd (TLSA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

TEVA currently trades at $35.32 with a QOC of 6.7/10, while TLSA trades at $1.41 with a QOC of 1.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).